Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones

被引:42
作者
Djimdé, AA
Dolo, A
Ouattara, A
Diakité, S
Plowe, CV
Doumbo, OK
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev, Malaria Sect, Baltimore, MD 21201 USA
[2] Univ Bamako, Fac Med Pharm & Dent, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali
[3] Minist Hlth, Natl Malaria Control Program, Bamako, Mali
基金
美国国家卫生研究院;
关键词
D O I
10.1086/422758
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasmodium falciparum mutations pfcrt K76T and the dhfr/dhps "quintuple mutant" are molecular markers of resistance to chloroquine and sulfadoxine-pyrimethamine, respectively. During an epidemic of P. falciparum malaria in an area of political unrest in northern Mali, where standard efficacy studies have been impossible, we measured the prevalence of these markers in a cross-sectional survey. In 80% of cases of infection, pfcrt K76T was detected, but none of the cases carried the dhfr/dhps quintuple mutant. On the basis of these results, chloroquine was replaced by sulfadoxine-pyrimethamine in control efforts. This example illustrates how molecular markers for drug resistance can provide timely data that inform malaria-control policy during epidemics and other emergency situations.
引用
收藏
页码:853 / 855
页数:3
相关论文
共 10 条
[1]   Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates [J].
Bickii, J ;
Basco, LK ;
Ringwald, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :243-247
[2]   Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali [J].
Diourté, Y ;
Djimdé, A ;
Doumbo, OK ;
Sagara, I ;
Coulibaly, Y ;
Dicko, A ;
Diallo, M ;
Diakité, M ;
Cortese, JF ;
Plowe, CV .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (03) :475-478
[3]  
Djimdé A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
[4]   Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria [J].
Djimdé, A ;
Doumbo, OK ;
Steketee, RW ;
Plowe, CV .
LANCET, 2001, 358 (9285) :890-891
[5]   Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: Relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome [J].
Khalil, I ;
Alifrangis, M ;
Ronn, AM ;
Gabar, HA ;
Jelinek, T ;
Satti, GMH ;
Bygbjerg, IBC .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2002, 67 (03) :225-229
[6]   Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria [J].
Kublin, JG ;
Dzinjalamala, FK ;
Kamwendo, DD ;
Malkin, EM ;
Cortese, JF ;
Martino, LM ;
Mukadam, RAG ;
Rogerson, SJ ;
Lescano, AG ;
Molyneux, ME ;
Winstanley, PA ;
Chimpeni, P ;
Taylor, TE ;
Plowe, CV .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (03) :380-388
[7]   Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? [J].
Omar, SA ;
Adagu, IS ;
Warhurst, DC .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (03) :315-319
[8]   Monitoring antimalarial drug resistance: making the most of the tools at hand [J].
Plowe, CV .
JOURNAL OF EXPERIMENTAL BIOLOGY, 2003, 206 (21) :3745-3752
[9]  
Rab MA, 2001, ANN TROP MED PARASIT, V95, P41, DOI 10.1080/00034980020035906
[10]   Chloroquine-resistant malaria [J].
Wellems, TE ;
Plowe, CV .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (06) :770-776